Better leukemia-free survival with allogeneic than with autologous HCT in AML patients with isolated trisomy 8: a study from the ALWP of the EBMT

MLA

Maija Itälä-Remes, et al. “Better Leukemia-Free Survival with Allogeneic than with Autologous HCT in AML Patients with Isolated Trisomy 8: A Study from the ALWP of the EBMT.” Bone Marrow Transplantation, vol. 56, Sept. 2020, pp. 461–69. EBSCOhost, https://doi.org/10.1038/s41409-020-01051-6.

APA

Maija Itälä-Remes, Gérard Socié, Ibrahim Yakoub-Agha, Mohamad Mohty, Frédéric Baron, Edouard Forcade, Myriam Labopin, Arnon Nagler, Jordi Esteve, Didier Blaise, & Norbert Claude Gorin. (2020). Better leukemia-free survival with allogeneic than with autologous HCT in AML patients with isolated trisomy 8: a study from the ALWP of the EBMT. Bone Marrow Transplantation, 56, 461–469. https://doi.org/10.1038/s41409-020-01051-6

Chicago

Maija Itälä-Remes, Gérard Socié, Ibrahim Yakoub-Agha, Mohamad Mohty, Frédéric Baron, Edouard Forcade, Myriam Labopin, et al. 2020. “Better Leukemia-Free Survival with Allogeneic than with Autologous HCT in AML Patients with Isolated Trisomy 8: A Study from the ALWP of the EBMT.” Bone Marrow Transplantation 56 (September): 461–69. doi:10.1038/s41409-020-01051-6.